



# Fig. S1




**B**

Effect of anti-Ly6G treatment on blood polymorphonuclear leukocytes counts			
	24h	48h	72h
Control IgG	5.7 ± 0.5*	6.8 ± 0.5	6.4 ± 0.7
Anti-Ly6G	0.6 ± 0.2	0.5 ± 0.2	0.6 ± 0.2

**C**




**D**



**Suppl. Fig. S1.** A. Gating strategy for identification of Ly6G<sup>+</sup> (neutrophils), CD11c<sup>+</sup> (dendritic cells) and F4/80<sup>+</sup> (macrophages) cells. Shown is a population of PLF cells collected at 48h after i.p. injection of GBS (5x10<sup>6</sup>CFU). B. Effect of anti-Ly6G treatment on blood polymorphonuclear leukocytes counts. Shown are percentages of Ly6G<sup>+</sup> cells in peripheral blood. All values are means ± SD. C. Purity of a representative neutrophil preparation. Ly6G<sup>+</sup> cells represent neutrophils, F4/40<sup>+</sup> cells macrophages and CD11c<sup>+</sup> cells dendritic cells, as determined by immuno-fluorescence flow-cytometry. (D) Cxcl1 and Cxcl2 production in bone-marrow-derived neutrophils before and after depletion of macrophages with anti-CD115 mAb-coated beads. Chemokines were measured at 24 h after treatment with increasing MOIs (2, 5, 10 and 20) of GBS. Data are expressed as means + SD of results from three independent experiments conducted in duplicate.

# Fig. S2



**Suppl. Fig. S2.** A and B. Effect of cycloheximide on Cxcl1/2 production by phagocytes. Bone-marrow-derived neutrophils or macrophages (both  $5 \times 10^5$  cells) were stimulated with GBS (MOI 5) in the presence or absence of cycloheximide (5 $\mu$ g/ml). Chemokine levels in supernatants were measured at 24 hours after culture. C and D. Cxcl1/2 production in bone-marrow-derived neutrophils and macrophages (both  $5 \times 10^5$  cells) treated with actinomycin D (5  $\mu$ g/ml) either at the same time as stimulation with GBS (MOI 5) or at 0.5, 1 and 2 h afterwards. Supernatants were collected at 4 h. E. Effect of neutralizing antibodies on neutrophil ROS production. Delta median fluorescence intensities ( $\Delta$ MFI) of GBS-stimulated neutrophils pretreated with neutralizing antibodies directed against Cxcl1, Cxcl2 or with control IgG. F. Concentrations of Cxcl2 in supernatants of bone marrow-derived neutrophils from mice with genetic defects in single or multiple endosomal TLRs. Supernatants were collected at 24 h after infection with GBS (MOI 5). In all panels, data are expressed as means + SD of three independent experiments conducted in duplicate. \*\*P < 0.01, \*\*\*P < 0.001, determined by unpaired t-test (A and B) or one-way ANOVA and Bonferroni post-test (E and F).